Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14685MR)

This product GTTS-WQ14685MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in B cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14685MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8669MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ7145MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ11466MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ11075MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ13335MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ10860MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ12733MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ10839MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M9346A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW